Mounjaro and Trulicity are both Eli Lilly products, both once-weekly subcutaneous injections, and both used for type 2 diabetes management. But they represent two different generations of GLP-1 therapy. Trulicity (dulaglutide) was Lilly's first major weekly GLP-1, approved in 2014. Mounjaro (tirzepatide) is the more recent dual-receptor agonist, approved in 2022, and represents a significant clinical advance over its older sibling. For most patients, Mounjaro is meaningfully more effective. Here's the complete comparison.
Quick Comparison: Mounjaro vs Trulicity
| Feature | Trulicity | Mounjaro |
|---|---|---|
| Active ingredient | Dulaglutide | Tirzepatide |
| Drug class | GLP-1 agonist (single) | GLP-1 + GIP agonist (dual) |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA approval | 2014 (T2D), 2020 (CV risk) | 2022 (T2D) |
| Dosing frequency | Once weekly | Once weekly |
| Available doses | 0.75mg, 1.5mg, 3mg, 4.5mg | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg |
| Average A1C reduction (max dose) | ~1.5-1.8% | ~2.0-2.4% |
| Average weight loss (max dose, T2D) | ~10 lbs | ~25 lbs |
| Pen design | Single-dose pre-filled pen | Single-dose KwikPen |
| List price | ~$998/month | ~$1,069/month |
Efficacy: Weight Loss and A1C Control
The SURPASS-5 trial directly compared Mounjaro to Trulicity in patients with type 2 diabetes. The results were stark:
| Outcome | Trulicity 1.5mg | Mounjaro 5mg | Mounjaro 15mg |
|---|---|---|---|
| A1C reduction | 1.4% | 1.9% | 2.4% |
| Weight loss | ~5 lbs | ~14 lbs | ~25 lbs |
| Patients reaching A1C <7% | 37% | 57% | 73% |
| Patients losing 5%+ body weight | 30% | 67% | 82% |
At every comparable dose level, Mounjaro produces greater weight loss and better A1C control than Trulicity. The 15mg Mounjaro dose more than doubles the average weight loss seen with maximum-dose Trulicity. For patients seeking significant metabolic improvement, the difference is clinically meaningful.
Why Mounjaro Works Better Than Trulicity
The fundamental difference is the receptor mechanism. Trulicity activates only the GLP-1 receptor — it's a single-mechanism drug. Mounjaro activates both the GLP-1 receptor AND the GIP receptor — it's a dual-mechanism drug. The addition of GIP receptor activation provides additional metabolic effects that GLP-1 alone cannot achieve.
In addition to the mechanism difference, tirzepatide is more potent than dulaglutide on a per-molecule basis. The maximum dose of Mounjaro (15mg) provides substantially more receptor activation than the maximum dose of Trulicity (4.5mg), even setting aside the dual-receptor advantage.
Side Effects Comparison
Both medications have similar side effect profiles dominated by GI symptoms. Trulicity tends to have slightly milder side effects at comparable efficacy levels because of its lower potency. Mounjaro at high doses has somewhat higher side effect rates than Trulicity, but with much greater clinical effect.
| Side Effect | Trulicity 4.5mg | Mounjaro 15mg |
|---|---|---|
| Nausea | 16% | 29% |
| Diarrhea | 13% | 21% |
| Vomiting | 9% | 15% |
| Decreased appetite | 8% | 18% |
| Constipation | 6% | 13% |
The trade-off is clear: Mounjaro produces dramatically more weight loss and better blood sugar control, at the cost of moderately higher side effect rates. Most patients consider this trade-off favorable, particularly given that side effects typically diminish over time while the metabolic benefits persist.
Cost: Mounjaro vs Trulicity
List prices are similar — both are around $1,000/month. Insurance coverage and savings programs determine the actual out-of-pocket cost.
| Cost Scenario | Trulicity | Mounjaro |
|---|---|---|
| List price | ~$998/month | ~$1,069/month |
| With manufacturer savings card | ~$25/month | ~$25/month |
| Average insurance copay (T2D coverage) | $25-$200 | $25-$200 |
| Manufacturer assistance program | Lilly Cares Foundation | Lilly Cares Foundation |
Both medications use the Eli Lilly savings card programs and the same Lilly Cares Foundation for income-qualified patients. Insurance coverage tends to be similar — most plans that cover one cover the other.
Switching From Trulicity to Mounjaro
Switching from Trulicity to Mounjaro is straightforward and common. The process:
- Stop Trulicity after your last scheduled dose
- Wait one week (the normal Trulicity dosing interval)
- Begin Mounjaro at 2.5mg (the standard starting dose), regardless of what Trulicity dose you were on
- Escalate Mounjaro normally on the standard schedule (2.5mg → 5mg → 7.5mg, etc.)
Most patients tolerate the switch well. Some experience a temporary increase in side effects in the first weeks as the body adjusts to tirzepatide and the dual-receptor mechanism. By week 4-6, most patients feel similar to or better than they did on Trulicity.
The clinical benefits of switching are typically apparent within 2-3 months: greater weight loss, lower A1C, and often better appetite control. For patients who plateaued on Trulicity or weren't reaching their treatment goals, switching to Mounjaro often produces significant additional improvement.
Frequently Asked Questions
Frequently Asked Questions
Is Mounjaro better than Trulicity?
For both weight loss and A1C reduction, Mounjaro substantially outperforms Trulicity in clinical trials. The SURPASS-1 and SURPASS-2 trials showed Mounjaro produced approximately 2-3x the weight loss and 0.5-1 percentage point greater A1C reduction compared to dulaglutide (Trulicity) at maximum doses.
Are Mounjaro and Trulicity made by the same company?
Yes — both are manufactured by Eli Lilly and Company. Trulicity (dulaglutide) was Lilly's earlier weekly GLP-1 medication, approved in 2014. Mounjaro (tirzepatide) is the more recent dual-receptor agonist from the same company, approved in 2022.
Can I switch from Trulicity to Mounjaro?
Yes. Many patients switch from Trulicity to Mounjaro for greater weight loss and blood sugar control. Your prescriber will determine the appropriate starting Mounjaro dose based on your current Trulicity dose. Most patients begin Mounjaro at 2.5mg or 5mg after stopping Trulicity, regardless of prior dulaglutide dose.
Why is Mounjaro more effective than Trulicity?
The mechanism difference is the primary reason. Trulicity is a single GLP-1 receptor agonist. Mounjaro is a dual GLP-1/GIP receptor agonist, meaning it activates two metabolic pathways simultaneously. This dual mechanism produces stronger effects on appetite, blood sugar, and weight than GLP-1 alone.